OSE Immunotherapeutics【OSE】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

6.62

買値

6.62

売値

6.64

出来高

49,444

6.45 日の範囲 6.65

3.115 52 週間の範囲 11.58

時価総額

144.103M

前日終値

6.41

始値

6.45

時刻

6.62

最終取引時間

21:37:26

財務取引量

VWAP

平均取引量 (3 か月)

123,791

発行済株式数

21,767,777

配当利回り

PER

-6.20

1 株当たり利益 (EPS)

-1.06

歳入

2.23M

純利益

-23M

セクター

Coml Physical, Biologcl Resh

業界

Coml Physical, Biologcl Resh

ウェブサイト

www.ose-immuno.com

本社

Nantes, Loire-atlantique, Fra

設立

OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the ユーロネクスト with ticker OSE. The last closing price for OSE Immunotherapeutics was 6.41 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 3.115 € to 11.58 €.

OSE Immunotherapeutics currently has 21,767,777 shares in issue. The market capitalisation of OSE Immunotherapeutics is 139.53 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.20.

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R...

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème congrès annuel de l’ECCO

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème congrès annuel de l’ECCO OSE Immunotherapeutics...

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13...

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant...

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO Un abstract clinique sur les...

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO A clinical abstract on the induction results from the CoTikiS...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.12	1.84615384615	6.5	6.76	6.24	69375	6.43272119	DE
4	-0.55	-7.67085076709	7.17	7.85	6.24	81634	6.8421712	DE
12	-4.16	-38.5899814471	10.78	11.18	6.24	123791	8.02796216	DE
26	-1.12	-14.4702842377	7.74	11.58	6.24	173754	8.35401259	DE
52	2.68	68.0203045685	3.94	11.58	3.115	172770	7.25001541	DE
156	-1.97	-22.9336437718	8.59	11.58	2.705	108630	6.30977439	DE
260	2.48	59.9033816425	4.14	15.8	2.705	102586	7.42969777	DE

OSE - Frequently Asked Questions (FAQ)

What is the current OSE Immunotherapeutics share price?

The current share price of OSE Immunotherapeutics is 6.62 €

How many OSE Immunotherapeutics shares are in issue?

OSE Immunotherapeutics has 21,767,777 shares in issue

What is the market cap of OSE Immunotherapeutics?

The market capitalisation of OSE Immunotherapeutics is EUR 139.53M

What is the 1 year trading range for OSE Immunotherapeutics share price?

OSE Immunotherapeutics has traded in the range of 3.115 € to 11.58 € during the past year

What is the PE ratio of OSE Immunotherapeutics?

The price to earnings ratio of OSE Immunotherapeutics is -6.2

What is the cash to sales ratio of OSE Immunotherapeutics?

The cash to sales ratio of OSE Immunotherapeutics is 64.03

What is the reporting currency for OSE Immunotherapeutics?

OSE Immunotherapeutics reports financial results in EUR

What is the latest annual turnover for OSE Immunotherapeutics?

The latest annual turnover of OSE Immunotherapeutics is EUR 2.23M

What is the latest annual profit for OSE Immunotherapeutics?

The latest annual profit of OSE Immunotherapeutics is EUR -23M

What is the registered address of OSE Immunotherapeutics?

The registered address for OSE Immunotherapeutics is 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200

What is the OSE Immunotherapeutics website address?

The website address for OSE Immunotherapeutics is www.ose-immuno.com

Which industry sector does OSE Immunotherapeutics operate in?

OSE Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MLSMLSmalto	0.029 € (87.10%)	130k
MLWEYWeya	0.026 € (73.33%)	3k
MLAATAzorean Tech	0.242 € (51.25%)	6.52k
AELISAelis Farma SA	4.10 € (34.87%)	35.15k
ALATAAtari SA	0.1495 € (21.05%)	2.8M
BIODSBiosynex DS	0.0301 € (-50.74%)	33.23k
ALCYBCybergun	0.0001 € (-50.00%)	10.65M
BE0945331669ARKimedes Fonds NV	5.00 € (-39.76%)	35
DRVDSDrone Volt DS	0.0003 € (-25.00%)	112.02k
ALWITWitbe	1.91 € (-23.90%)	46.67k
ATOAtos SE	0.002 € (-4.76%)	457.44M
BCPBanco Comercial Portugues SA	0.5014 € (-0.20%)	18.98M
ALVERVergnet	0.0013 € (-7.14%)	18.15M
ALHPIHopium SA	0.0033 € (-2.94%)	12.6M
ALNRGEnergisme SA	0.0049 € (2.08%)	10.93M